These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19183932)

  • 1. PPARGC1A sequence variation and cardiovascular risk-factor levels: a study of the main genetic effects and gene x environment interactions in children from the European Youth Heart Study.
    Brito EC; Vimaleswaran KS; Brage S; Andersen LB; Sardinha LB; Wareham NJ; Ekelund U; Loos RJ; Franks PW
    Diabetologia; 2009 Apr; 52(4):609-13. PubMed ID: 19183932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose levels and genetic variants across transcriptional pathways: interaction effects with BMI.
    Povel CM; Feskens EJ; Imholz S; Blaak EE; Boer JM; Dollé ME
    Int J Obes (Lond); 2010 May; 34(5):840-5. PubMed ID: 20125101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for interaction between PPARG Pro12Ala and PPARGC1A Gly482Ser polymorphisms in determining type 2 diabetes intermediate phenotypes in overweight subjects.
    Ruchat SM; Weisnagel SJ; Vohl MC; Rankinen T; Bouchard C; Pérusse L
    Exp Clin Endocrinol Diabetes; 2009 Oct; 117(9):455-9. PubMed ID: 19536736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Am J Clin Nutr; 2013 Feb; 97(2):326-31. PubMed ID: 23269818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention.
    Stefan N; Thamer C; Staiger H; Machicao F; Machann J; Schick F; Venter C; Niess A; Laakso M; Fritsche A; Häring HU
    J Clin Endocrinol Metab; 2007 May; 92(5):1827-33. PubMed ID: 17327385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exonic peroxisome proliferator-activated receptor-γ coactivator-1α variation may mediate the resting energy expenditure through a potential regulatory role on important gene expression in this pathway.
    Mirzaei K; Hossein-nezhad A; Emamgholipour S; Ansar H; Khosrofar M; Tootee A; Alatab S
    J Nutrigenet Nutrigenomics; 2012; 5(2):59-71. PubMed ID: 22652814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes.
    Barroso I; Luan J; Sandhu MS; Franks PW; Crowley V; Schafer AJ; O'Rahilly S; Wareham NJ
    Diabetologia; 2006 Mar; 49(3):501-5. PubMed ID: 16435105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARGC1A variation associated with DNA damage, diabetes, and cardiovascular diseases: the Boston Puerto Rican Health Study.
    Lai CQ; Tucker KL; Parnell LD; Adiconis X; García-Bailo B; Griffith J; Meydani M; Ordovás JM
    Diabetes; 2008 Apr; 57(4):809-16. PubMed ID: 18162502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between the PPARGC1A Gly482Ser polymorphism and muscle fitness in Chinese schoolchildren.
    Wei Q
    PLoS One; 2023; 18(4):e0284827. PubMed ID: 37104269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program.
    Franks PW; Christophi CA; Jablonski KA; Billings LK; Delahanty LM; Horton ES; Knowler WC; Florez JC;
    Diabetologia; 2014 Mar; 57(3):485-90. PubMed ID: 24317794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the association between the PPARGC1A genetic polymorphisms and type 2 diabetes in Han Chinese population.
    Zhu S; Liu Y; Wang X; Wu X; Zhu X; Li J; Ma J; Gu HF; Liu Y
    Diabetes Res Clin Pract; 2009 Dec; 86(3):168-72. PubMed ID: 19828207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men.
    Ridderstråle M; Johansson LE; Rastam L; Lindblad U
    Diabetologia; 2006 Mar; 49(3):496-500. PubMed ID: 16474966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge.
    Franks PW; Ekelund U; Brage S; Luan J; Schafer AJ; O'Rahilly S; Barroso I; Wareham NJ
    Diabetologia; 2007 Mar; 50(3):569-73. PubMed ID: 17216277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE I/D, ACTN3 R577X, PPARD T294C and PPARGC1A Gly482Ser polymorphisms and physical fitness in Taiwanese late adolescent girls.
    Chiu LL; Chen TW; Hsieh SS; Hsieh LL
    J Physiol Sci; 2012 Mar; 62(2):115-21. PubMed ID: 22247001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the PPARGC1A polymorphism and aerobic capacity in Japanese middle-aged men.
    Nishida Y; Iyadomi M; Higaki Y; Tanaka H; Kondo Y; Otsubo H; Horita M; Hara M; Tanaka K
    Intern Med; 2015; 54(4):359-66. PubMed ID: 25748950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haplotypes of PPARGC1A are associated with glucose tolerance, body mass index and insulin sensitivity in offspring of patients with type 2 diabetes.
    Pihlajamäki J; Kinnunen M; Ruotsalainen E; Salmenniemi U; Vauhkonen I; Kuulasmaa T; Kainulainen S; Laakso M
    Diabetologia; 2005 Jul; 48(7):1331-4. PubMed ID: 15912394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men.
    Lucia A; Gómez-Gallego F; Barroso I; Rabadán M; Bandrés F; San Juan AF; Chicharro JL; Ekelund U; Brage S; Earnest CP; Wareham NJ; Franks PW
    J Appl Physiol (1985); 2005 Jul; 99(1):344-8. PubMed ID: 15705733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTR1B, ADIPOR1, PPARGC1A, and CYP19A1 and obesity in a cohort of Caucasians and African Americans: an evaluation of gene-environment interactions and candidate genes.
    Edwards TL; Velez Edwards DR; Villegas R; Cohen SS; Buchowski MS; Fowke JH; Schlundt D; Long J; Cai Q; Zheng W; Shu XO; Hargreaves MK; Smith J; Williams SM; Signorello LB; Blot WJ; Matthews CE
    Am J Epidemiol; 2012 Jan; 175(1):11-21. PubMed ID: 22106445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Gly482Ser genotype at the PPARGC1A gene and elevated blood pressure: a meta-analysis involving 13,949 individuals.
    Vimaleswaran KS; Luan J; Andersen G; Muller YL; Wheeler E; Brito EC; O'Rahilly S; Pedersen O; Baier LJ; Knowler WC; Barroso I; Wareham NJ; Loos RJ; Franks PW
    J Appl Physiol (1985); 2008 Oct; 105(4):1352-8. PubMed ID: 18467552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor gamma/Pro12Ala polymorphism and peroxisome proliferator-activated receptor gamma coactivator-1 alpha/Gly482Ser polymorphism in patients with sarcoidosis.
    Maver A; Medica I; Salobir B; Tercelj-Zorman M; Sabovic M; Petrovic D; Peterlin B
    Sarcoidosis Vasc Diffuse Lung Dis; 2008 Sep; 25(1):29-35. PubMed ID: 19070258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.